0001493152-22-019853.txt : 20220719
0001493152-22-019853.hdr.sgml : 20220719
20220719170159
ACCESSION NUMBER: 0001493152-22-019853
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20220719
DATE AS OF CHANGE: 20220719
EFFECTIVENESS DATE: 20220719
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Arch Therapeutics, Inc.
CENTRAL INDEX KEY: 0001537561
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 460524102
STATE OF INCORPORATION: NV
FISCAL YEAR END: 0930
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-452969
FILM NUMBER: 221092104
BUSINESS ADDRESS:
STREET 1: 235 WALNUT STREET, SUITE 6
CITY: FRAMINGHAM
STATE: MA
ZIP: 01702
BUSINESS PHONE: 617-431-2313
MAIL ADDRESS:
STREET 1: 235 WALNUT STREET, SUITE 6
CITY: FRAMINGHAM
STATE: MA
ZIP: 01702
FORMER COMPANY:
FORMER CONFORMED NAME: ALMAH,INC
DATE OF NAME CHANGE: 20111216
D
1
primary_doc.xml
X0708
D
LIVE
0001537561
Arch Therapeutics, Inc.
235 WALNUT STREET, SUITE 6
FRAMINGHAM
MA
MASSACHUSETTS
01702
617-431-2313
NEVADA
Almah, Inc.
ALMAH,INC
Corporation
true
Terrence
W.
Norchi
235 Walnut Street, Suite 6
Framingham
MA
MASSACHUSETTS
01702
Executive Officer
Director
Punit
Dhillon
235 Walnut Street, Suite 6
Framingham
MA
MASSACHUSETTS
01702
Director
Laurence
Hicks
235 Walnut Street, Suite 6
Framingham
MA
MASSACHUSETTS
01702
Director
Guy
Fish
236 Walnut Street, Suite 6
Framingham
MA
MASSACHUSETTS
01702
Director
Michael
S.
Abrams
235 Walnut Street, Suite 6
Framingham
MA
MASSACHUSETTS
01702
Executive Officer
Daniel
M.
Yrigoyen
235 Walnut Street, Suite 6
Framingham
MA
MASSACHUSETTS
01702
Executive Officer
Biotechnology
Decline to Disclose
- 06b
false
2022-07-06
false
true
true
false
0
Maxim Group LLP
120708
None
None
300 PARK AVE, 16TH FLOOR
NEW YORK
NY
NEW YORK
10022
All States
false
4230000
4230000
0
false
16
240000
true
0
Some of the proceeds may be used for general working capital purposes including the payment of salaries and other fees to those listed in Item 3. Additionally, warrants were issued to the placement agent at an exercise price of $0.0503 per share.
0
true
false
Arch Therapeutics, Inc.
/s/ Michael S. Abrams
Michael S. Abrams
Chief Financial Officer
2022-07-19